Bright Minds Biosciences Inc. NASDAQ: DRUG

What we’re investigating

Henzel Law is investigating potential claims on behalf of shareholders of Bright Minds Biosciences Inc. (NASDAQ: DRUG), a clinical-stage company developing BMB-101, a serotonin receptor agonist, for epilepsy and related disorders. The investigation concerns the Company’s January 2026 public offering and the disclosures that preceded it. No lawsuit has been filed yet in this matter.

The firm is particularly interested in hearing from investors who purchased Bright Minds shares in or traceable to the January 2026 offering.

The offering

On January 6, 2026, Bright Minds announced positive topline results from a Phase 2 trial of BMB-101, stating that the drug “was generally well tolerated” with “no treatment-related serious adverse events,” and that it had “initiated preparations for global registrational trials in Absence Seizures and DEE.”

Days later, on January 9, 2026, the Company closed a registered public offering of 1,945,000 common shares at $90.00 per share, raising approximately $175 million in gross proceeds. The offering was made under a shelf registration statement, and the prospectus supplement incorporated by reference the Company’s annual filings dated December 23, 2025. Those filings stated, in a program-by-program table, that the “IND-enabling package” for BMB-101 was “completed.”

What happened on November 2, 2026

Before the market opened on November 2, 2026, Bright Minds disclosed that the U.S. Food and Drug Administration had placed a partial clinical hold on its planned Phase 2 trial of BMB-101 in developmental and epileptic encephalopathies. The Company said the primary reason given by the FDA “relates to identified toxicity in mice,” together with pharmacokinetic and juvenile toxicity data the agency considered inadequate to support enrolling children.

The Company stated its belief that the adverse findings in mice “were incidental and not drug-related,” expressly noting that this is the Company’s view and should not be understood as the FDA’s findings. It said it was awaiting the agency’s full letter.

The share price fell from $54.98 to $26.20, a decline of approximately 52.4%.

What the investigation is examining

The question is whether the offering materials, and the annual filings they incorporated, fairly described the state of the preclinical package supporting BMB-101 — in particular the statement that the IND-enabling package was complete.

One disclosure in those filings deserves close attention. The Company had disclosed that it previously submitted an investigational new drug application to the FDA and withdrew it before full review, and that the agency’s withdrawal letter “mentioned partial clinical hold deficiencies.” But that disclosure attributed those deficiencies to the proposed dosing regime — not to toxicity findings, not to animal data, and not to the pharmacokinetic or juvenile toxicity package that the FDA identified in November 2026. Whether a warning about one subject gives fair notice of a different one is a central issue here.

Claims arising from a registered public offering are brought under the Securities Act of 1933 and do not require an investor to prove that anyone intended to deceive. That is why purchasers in or traceable to the January 2026 offering are the investors the firm most wants to hear from.

The investigation is also weighing what cuts against a claim. The Company’s public statements about BMB-101’s safety described clinical experience in adults — roughly 90 subjects across its programs, none of them children — and those statements appear to remain accurate. The FDA’s concern is with nonclinical and pediatric data that no completed trial addressed.

Who this may affect

Investors who purchased Bright Minds Biosciences Inc. (NASDAQ: DRUG) common shares in or traceable to the January 2026 public offering, or who purchased during the period under review and lost money, may have been affected. That period is the firm’s own estimate for purposes of this investigation; it has not been set or approved by any court. Nothing on this page is an assertion that the Company or any of its officers or directors has been found to have violated any law. If you have questions about your Bright Minds holdings, you are welcome to submit your information below for a free, no-obligation review.